Melasma is a refractory skin disease due to its complex pathogenesis and difficult treatment. Studies have found that human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSC-Exos) could serve as a novel cell-free therapeutic strategy in regenerative and aesthetic medicine. It could potentially treat melasma, but the skin barrier is a challenge. This study aims to explore the safety and efficacy of hUCMSC-Exos in the treatment of melasma and means to promote its percutaneous penetration.
None
Patients who refuse to sign the informed consent form to participate in the trial;
Those with a history of important organ diseases, or a history of autoimmune diseases or immune dysfunction;
Abnormal coagulation function, current use of anticoagulants, thrombophilia and history of familial genetic diseases;
Pregnant or lactating women;